Which sort of people may benefit from GLP-1 agonist?

Inhibitors in the UK are licensed for patients who are on quite big dosages of insulin, which essentially in our language more than 100 units a day. Patients with BMI of more than 35 kilograms per meter square, which essentially people who are classified to be obese, patients who have underlying diabetes and they have either of the above two we've discussed and patients who are having side effects from using using using other modalities or oral therapies, which can lead to weight gain. So a lot of oral therapies in diabetes, like glycoside, could lead to weight gain and GLP1s are medications which are associated with weight loss. So these patients are eligible for GLP1 therapy, but strictly speaking within UK is based on the BMI, which is essentially the body weight, and also predominantly around the body weight marker.